Malignant transformation of human cells may be associated with changes in the expression of histocompatibility antigens and the appearance of antigenic structures undetectable in their normal counterparts. Lysis of neoplastic cells by cytotoxic T-lymphocytes depends upon the expression of class I antigens in association with tumour antigens (Zinkernagel & Doherty, 1979) whereas MHC class II molecules are required for the presentation of tumour associated antigens to helper T-cells (Benacerraf, 1981; Lonai et al., 1981) . However, there was no correlation between the expression of MHC antigens and the extent and type of mononuclear tumour infiltrate (Csiba et al., 1984; Whitwell et al., 1984) . Furthermore, Rognum et al., 1983 demonstrated that homogenous expression of CEA and HLA-DR in colorectal tumours was clearly associated with increasing tumour dissemination as measured by Dukes' staging (Dukes, 1932) .
Experiments with murine models have illustrated the importance of MHC antigen expression in the immunology of the tumour-host relationship (reviewed by . For example, several homozygous and heterozygous tumours expressing cnly one H-2 antigen can be transfected with the missing gene and express the relevant H-2 molecule(s) (Hui et al., 1984; Wallich et al., 1985) . This led to tumour rejection in some cases and to abrogation of metastases in others. In other models, H-2 deficient variants may be selectively rejected (Karre et al., 1986) . It is therefore conceivable that the level of MHC antigen expression may be an important factor in determining the growth and metastatic properties of certain human tumours, although high levels of expression may not necessarily be associated with more effective recognition.
A rapid and accurate screen for quantitating MHC antigen expression on individual tumour cells has therefore been developed. The level of HLA-ABC and HLA-DR antigen was assessed on a series of colorectal tumours in relation to histological grade, clinicopathological stage, expression of tumour associated antigens, DNA ploidy and early in vitro growth.
Materials and methods
Tumour cells Tumour cell suspension was prepared from tissue within 18 h of removal. No loss in cell viability was observed in this time period. Tissue was finely minced and disaggregated in 0.05% collagenase (Boehringer, Mannheim, West Germany) as previously described (Durrant et al., 1986a) .
Monoclonal antibodies
Antibodies to MHC antigens HLA-ABC was detected by monoclonal antibody W6/32 (Seralab, UK) which recognises a determinant co-expressed on MHC class I heavy and light chain (Barnstable et al., 1978) . HLA-DR was detected by RF-B-HLA-DR (Seralab, UK) which recognised a monomorphic determinant on HLA-DR molecules (Bodger et al., 1983) . Antibodies to tumour associated antigens A panel of 3 murine monoclonal antibodies reactive with tumour associated antigens was used in this study. 79IT/36 antibody recognises a glycoprotein of mol. wt. 72,000 (79 IT p72) which is found in a wide variety of tumours (Embleton et al., 1981; Price et al., 1983 ) C14 antibody recognises a difucosylated type 2 blood group antigen (Brown et al., 1983) . 365 antibody recognises an epitope expressed on CEA but does not cross react with NCA.
filter centred at 515 nm and adjusted to standard conditions using fluorochrome labelled latex beads. Fluorescence intensity is expressed as mean linear fluorescence (MLF), calculated by multiplying the contents of each channel by its channel number and dividing by the total number of cells in the distribution (Roe et al., 1985 DNA analysis DNA was stained with mithramycin as previously described (Durrant et al., 1986a) . The DNA index was calculated as the ratio of the mean relative DNA content of the G0/GI cells of the sample divided by the mean of the relative DNA measurement of the diploid GO/GI reference cells. Cells with a normal diploid karyotype have by definition a DNA index of 1.0. Tumour cells were defined as having an aneuploid DNA content if their DNA index was between 1.1-1.9 and greater than 10% of the total cells produced the abnormal GO/G1 peak or if the index was between 1.9-2.1 if greater than 15% of the total cells produced the second peak. If this peak comprised less than 15% of the total cell population it is assumed to be the G2 peak of diploid cells.
Clinicopathology
All tumour were staged according to Dukes' staging (Dukes, 1932) plus Stage D for distant metastases, and histologically graded as well, moderately or poorly differentiated by standard criteria.
Cell culture materials The basal medium consisted of Dulbecco's minimal essential medium (DMEM) supplemented with 10% heat inactivated foetal calf serum (Gibco, Paisley).
Primary culture and passage Isolation and culture of C170, C146 and C168 cells has previously been described (Durrant et al., 1986b) . Cell lines 223, 224 and 225 were isolated and cultured by similar procedures. Cell lines 277 and 280 were isolated from fresh tumours as previously described (Durrant et al., 1986a) (Holmes et al., 1984 (Roe et al., 1985) . The majority of tumours (47%) stained in the range of MLFs of 500-1,000. Twenty four percent stained with a MLF > 1,000, 19% stained with an MLF < 500 and 10% failed to stain (MLF < 100). Two of the negative tumours stained with monoclonal antibody W6/32 following fixation. There was no obvious correlation with intensity of staining and either clinicopathological stage or histological grade, although the four negative tumours were from clinicopathological stages A, B and D whereas all the Dukes' C tumours stained with an MLF in excess of 700.
RF-B-HLA-DR monoclonal antibody reacted with colorectal tumours with a lower intensity (range of MLF 0-820; . However the variation in intensities between individual tumours was much clearer by FACS IV analysis of freshly stained cells.
Immunohistochemical staining of normal large bowel showed uniform staining with W6/32 monoclonal antibody and no HLA-DR staining (data not shown). 
Expression of MHC antigens on colorectal cells growing in early in vitro culture
In contrast to the primary tumours, where 90% stained with monoclonal antibody W6/32, only two of the eight tumours which grew in vitro expressed HLA-ABC antigens at their cell surface. However, seven out of eight of these cultures expressed internal HLA-ABC antigens which were detected in fixed but not fresh cells (Table V) . Only one of the cell lines expressed HLA-DR on its membrane whereas 50% of the primary tumours reacted with the RF-B-HLA-DR monoclonal antibody. However, 75% of these cultures expressed internal HLA-DR antigen which could be detected by RF-B-HLA-DR in fixed cells. (Table V) . Furthermore two of the cell lines, C170 and C168 could be induced to express HLA-DR at their cell surface (Figure 1) .
All of the early in vitro cultures expressed the tumour associated antigens defined by the monoclonal antibodies C14 and 791T/36 (Table V) (Table VI) . Only one of the aneuploid tumours stained heterogeneously whereas over half of the diploid tumours showed this patchy expression. Eighty percent of the aneuploid tumours expressed HLA-DR whereas only 27% of diploid tumours expressed this antigen.
Expression of HLA-ABC and HLA-DR antigens in relation to tumour associated antigens Seventy-three percent of the tumours, in which > 75% of the cells expressed HLA-ABC, also expressed the epitopes defined by monoclonal antibodies C14, 365 and 791T/36 (Table VII) . Only 50% of the tumours staining heterogeneously, and none of the tumours failing to stain with monoclonal antibody W6/32, co-expressed the three tumour associated antigens. One hundred percent of the tumours which failed to express HLA-ABC only co-expressed one tumour associated antigen. HLA-ABC was never expressed on its own (Table VII) . There was no correlation between the intensity of staining with W6/32 monoclonal antibody and the monoclonal antibodies RF-B-HLA-DR, C14, 365 and 791T/36 (Table VIII) .
All of the tumours in which >75% of the cells stained with RF-B-HLA-DR co-expressed the epitopes defined by monoclonal antibodies C14, 365 and 791T/36. Seventy-five percent of tumours staining heterogeneously with monoclonal antibody RF-B-HLA-DR and 52% of the tumours which failed to stain, also stained with monoclonal antibodies C14, 365 and 791T/36. Thirty-two percent of the tumours which failed to express HLA-DR antigen only coexpressed one of the tumour associated antigens. HLA-DR antigen was never expressed on its own. (Ljunggren & Karre, 1985) . Studies with rat tumour cells indicated that the appearance of increased class I antigen induced by rat yIFN closely parallels changes in sensitivity to natural killer cells (Yeoman et al., 1986) .
Although there was no correlation between the intensity of staining with W6/32 monoclonal antibodies and either histological grade or clinicopathological stage A, it will be interesting to see if there is any subsequent correlation with patient survival. In the mouse TIO sarcoma model manipulations which resulted in increased class I antigen expression were associated with increased metastatic potential (Katzav et al., 1983) . This was related to high levels of H-2D expression whereas gene transfection studies in the same lines showed that increased H-2K gene expression resulted in variants with decreased metastatic activity. Furthermore, this effect was related to an immune response, as the same variants metastasized in immunodeprived recipients (Wallich et al., 1985) . These findings are consistent with the hypothesis that tumour associated antigens are recognised in the context of H-2K and not H-2D class I antigens. Further studies using monoclonal antibodies specific to each of the human class I loci will determine if any one MHC class locus is a better indicator of tumour aggression.
Epithelial cells do not usually express HLA-DR antigens however 50% of the colorectal tumours expressed this antigen. Although the intensity of staining varied enormously (range of MLFs of 0-810), the majority of tumours stained weakly (MLF < 300). All of the poorly differentiated tumours expressed HLA-DR confirming the suggestion of Rognum et al. (1983) that HLA-DR expression is more consistent in poorly differentiated tumours. In agreement with previous studies (Daar & Fabre, 1983; Csiba et al., 1984) there was no correlation between expression of HLA-DR antigen and clinicopathological stage. Expression of HLA-DR antigens on primary tumours can augment the immunogenicity of tumour associated antigens as they are important in antigen presentation to helper T-lymphocytes . However, metastatic melanoma cells expressing high levels of HLA-DR antigens can inhibit the immune response of autologous peripheral blood lymphocytes. Furthermore it appears that a T-lymphocyte-derived lymphokine such as yIFN can influence both the phenotype and the suppressive activity of autologous metastatic melanoma cells .
Although Thompson et al. (1982) reported that metastatic colorectal tumours were consistently HLA-DR antigen negative, 2/4 of our secondary tumours expressed this antigen. However, it was found that the majority of early derived in vitro dividing cells were consistently negative for both HLA-ABC and HLA-DR antigens. However, reexpression of MHC antigens could be induced in several cell lines by the immune regulator yIFN. This could imply that antigen expression in vivo is induced by local yIFN, and the lack of expression in vitro is due to lack of yIFN. Alternatively if there is a correlation between in vitro and in vivo growth perhaps tumours are maintained and seed by cell surface MHC antigen negative cells which may escape immune recognition. Re-expression on maturation may be controlled by immune regulators such as yIFN.
In agreement with Rognum et al. (1982) the aneuploid tumours stained more homogeneously with RF-B-HLA-DR and with a higher intensity than the diploid tumours. This study also showed a similar correlation with expression of HLA-ABC antigens. Abnormal expression of the tumour associated antigens CEA, Y haptenic blood group and 791T p72 also correlated with expression of HLA-ABC and HLA-DR antigens on colorectal tumours. Previous studies show that tumour associated antigens are also expressed more strongly on aneuploid than diploid tumours (Durrant et al., 1 986a) . Perhaps gene amplification in aneuploid tumours results in increased antigen expression. Our group has previously shown that patients with aneuploid tumours have a significantly worse survival than patients with diploid tumours (Armitage et al., 1985) . Perhaps elevated HLA-class I expression is associated with increased metastatic potential as seen in animal models (Katzav et al., 1983) .
Prospective studies currently in progress should determine if the quantity of MHC antigens on human colorectal cancer correlates with tumour recurrence, and metastatic spread, allowing an early prediction of which stage B and C tumours are most aggressive.
